Moderna withdraws application for flu/COVID vaccine

Moderna (MRNA) has withdrawn its application for its mRNA-1083 flu/COVID combination vaccine for adults over 50 after consultation with the FDA, citing a strategic decision to incorporate efficacy data from the ongoing Phase 3 trial of its mRNA-1010 seasonal influenza vaccine; the company plans to resubmit the application later this year. This announcement follows a recent report of Moderna's Q1 2025 results, which showed a narrower-than-expected loss of -$2.52 EPS on $108 million in revenue, though revenue fell short of forecasts, and comes amid potential changes to COVID-19 booster requirements and recommendations from the FDA and HHS, respectively.

Analysis

Moderna, Inc. (NASDAQ:MRNA) has voluntarily withdrawn its U.S. Food and Drug Administration (FDA) application for mRNA-1083, its combination flu/COVID vaccine candidate for adults over 50, with plans to resubmit later this year incorporating forthcoming efficacy data from its mRNA-1010 seasonal influenza vaccine Phase 3 trial, interim results of which are expected this summer. This strategic decision follows a Q1 2025 financial report where Moderna posted a narrower-than-expected loss per share of -$2.52, beating the anticipated -$3.18, despite revenue of $108 million falling short of the $115.3 million forecast and representing a 38.35% decline over the last twelve months. While the company maintains strong liquidity with a current ratio of 4.22 and has demonstrated effective cost management, analysts have recently revised earnings expectations downward. The regulatory landscape presents further challenges, with the FDA planning to require new clinical trials for annual COVID-19 boosters for healthy individuals under 65, and the Department of Health and Human Services (HHS) set to discontinue routine COVID-19 vaccine recommendations for certain groups, potentially impacting future vaccine demand for manufacturers like Moderna. InvestingPro analysis notes the stock as undervalued, though recognizes the significant revenue headwinds.

Key Decisions for Investors

• Investors should monitor the upcoming interim Phase 3 data for mRNA-1010 this summer, as this will be critical for the planned resubmission of the mRNA-1083 combination vaccine and could serve as a key catalyst.
• Consider the near-term uncertainty introduced by the BLA withdrawal and resubmission timeline, alongside the ongoing revenue decline and downward earnings revisions, despite recent cost control successes and a better-than-expected Q1 EPS.
• Closely track evolving FDA and HHS guidelines regarding COVID-19 booster requirements and recommendations, as these will significantly influence the commercial outlook for Moderna's COVID-related product pipeline.
• Evaluate the current valuation, noted as potentially undervalued, against the backdrop of significant revenue pressures and the execution risk associated with its pipeline advancements and regulatory approvals in a shifting market.